This HTML5 document contains 61 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
schemahttp://schema.org/
rdfshttp://www.w3.org/2000/01/rdf-schema#
skoshttp://www.w3.org/2004/02/skos/core#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
n9http://dx.doi.org/10.1200/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n8http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q80358623
rdf:type
wikibase:Item
schema:description
наукова стаття, опублікована в травні 2007 artículu científicu espublizáu en mayu de 2007 wetenschappelijk artikel scientific article published on 01 May 2007
p:P577
wds:Q80358623-010B1417-22A0-4365-85D8-A52DA1D53DB5
wdt:P577
2007-05-01T00:00:00Z
p:P2093
wds:Q80358623-2E652024-B4D6-4D5F-8B49-F114BA00048E wds:Q80358623-2FCAD989-6976-4A42-874B-1B833595230B wds:Q80358623-0E4B2439-6186-426E-B0AC-D96180712CCF wds:Q80358623-2002CF67-8A66-4EE6-9797-14159174DEE2 wds:Q80358623-3CE7DE2A-7281-458E-8674-0DFDC8A988C2 wds:Q80358623-3D4DC507-284B-4495-8707-D7EE95EB4766 wds:Q80358623-38636FAD-8A66-447F-89F3-78350113DBA6 wds:Q80358623-46457773-3785-4E91-BB5C-24169F9E5F8C wds:Q80358623-484A7579-68C1-4711-888E-D1AA4DDB6CD5 wds:Q80358623-AD658B13-85EE-477E-BFB3-2E3DC5F7A371 wds:Q80358623-86CB22ED-A8AF-4EC3-B3DF-00E6E40B9FBE wds:Q80358623-8BAC03D8-90DD-413D-ABFC-97FF5D7E07A7 wds:Q80358623-B0414579-41EE-42C5-A73F-60B8583995F1 wds:Q80358623-B264FF05-C858-49C4-832D-51699D1CA4F7
wdt:P2093
Mayer Fishman Ronald DeConti Ji Hyun Lee Morgen Schmitt Elona Bicaku Alberto Chiappori Pamela Münster Douglas Marchion Richard Lush Susan Minton George Simon Adil Daud Chris Garrett Daniel Sullivan
rdfs:label
Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study
skos:prefLabel
Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study
schema:name
Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study
p:P1476
wds:Q80358623-CB8F2B62-3E60-4BCF-A63F-433875032299
wdt:P1476
Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study
p:P304
wds:Q80358623-7A6BE21D-78A4-4C9B-ABBA-AC3D633B8EF2
wdt:P304
1979-1985
p:P31
wds:Q80358623-C1C67A77-60B5-4CD9-BAB7-CD1DDB94B239
wdt:P31
wd:Q13442814
p:P921
wds:Q80358623-C0CC28AB-3373-47AE-B0BC-ABEC92F3C2A8
wdt:P921
wd:Q5452194
p:P698
wds:Q80358623-9A6476DC-3354-472A-9461-AB9D83D5EE2E
wdtn:P698
n8:17513804
wdt:P698
17513804
p:P1433
wds:Q80358623-F8763A0E-F1D1-42C1-93E4-92BB0E2AB25E
wdt:P1433
wd:Q400292
p:P433
wds:Q80358623-60649531-E639-406D-BB7A-BF63C1B10173
p:P478
wds:Q80358623-E9026EC4-FC40-45D5-8CA4-27ED69DD917F
wdt:P433
15
wdt:P478
25
p:P356
wds:Q80358623-34E2880D-8995-4670-93C9-D493B37F6CBB
wdtn:P356
n9:JCO.2006.08.6165
wdt:P356
10.1200/JCO.2006.08.6165